Cardiovascular disease related to immune therapy: JACC: CardioOncology special focus issue

Cardiovascular Disease Related to Immune Therapy: JACC: CardioOncology Special Focus Issue – JACC: CardioOncology

Homepage: Special Focus Issue: Immune Therapy

Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review

Cancer Immunotherapy Beyond Checkpoint Blockade: JACC: CardioOncology State-of-the-Art Review

Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management: JACC: CardioOncology State-of-the-Art Review

Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer

What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?

The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity

Related:

Cardiovascular complications of immune checkpoint inhibitors for cancer – European Heart Journal

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program – Journal of Clinical Oncology

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment – Journal of the American Heart Association

Cardiotoxicity of immune checkpoint inhibitors – ESMO Open

Cardiotoxicity from immune checkpoint inhibitors – IJC Heart & Vasculature

Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology – Journal of the Formosan Medical Association

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock – JACC: CardioOncology